Commercialising matrix biology
CSIRO's matrix biology research seeks to develop and characterise improved biomaterials based on naturally occurring extracellular matrix molecules.
CSIRO develops medical and biomedical textiles for applications in healthcare, regenerative medicine and tissue repair.
Automated image technologies enhance drug discovery
CSIRO’s automated image analysis technology can rapidly and accurately measure tiny changes in cells, to find safer drugs more quickly.
CSIRO is helping pharmaceutical companies with one of their most expensive, time-consuming tasks - identifying which chemical compounds to develop into new drugs.
Health information and patient management
New health management systems, through the applications of advanced information and communication technology, data analysis and statistics, are delivering improved patient treatments and new ways to retrieve, organise and communicate healthcare data.
Wireless detection of the early signs of heart disease
Non-invasive heart monitoring technology invented and patented by CSIRO has been licensed to a specialist medical technology company for further development. Researchers at Monash University are working on clinical validation of CSIRO's prototype.
Fighting Nipah virus
In 1998-99, an outbreak of a new virus now called Nipah virus killed more than 100 people and thousands of pigs in Malaysia.
CSIRO’s expertise in diagnosis and associated technologies enables faster drug discovery, personalised medicine and development of simpler clinical diagnostic tests.
CSIRO’s diagnostics research and development activity aims to reduce the impacts of some of Australia’s major diseases through earlier diagnosis.
Finally, a cure for flu
This video looks at how CSIRO solved the structure of a flu virus surface protein and led the development of the first anti-viral flu drug effective against all strains of flu. (3:00)
Computer aided drug discovery
CSIRO has developed a powerful software modelling tool, MolSAR, which has the potential to reduce drug development costs by up to US$50 million per drug.
Platform technology for cellular therapies
CSIRO’s IP is a platform technology for the rapid expansion of cells whilst maintaining phenotype. The technology will be useful for a wide range of cellular therapies and tissue engineering applications. (2 pages)
Carbon Nanotube Yarn
CSIRO research is supporting the development of revolutionary new products and processes in medicine, environmental management and energy.
A video clip illustrating the process of growing fibroblast cells on to carbon nanotube yarns for possible applications in tissue engineering. (0:30)